Following a story · 2 updates
Supernus and Indivior merge into $2.2 billion CNS drugmaker
Aug 3, 2026 – Aug 11, 2026
-
Supernus and Indivior merge as equals into $2.2 billion CNS drugmaker
Indivior shareholders will hold about 56.5 percent of the combined company, named Supernus, Inc., and receive a $1.0 billion cash dividend before closing, in an all-stock deal expected to close in the fourth quarter of 2026.
Read this issue → -
Supernus and Indivior merge into $2.2 billion CNS drugmaker
Supernus Pharmaceuticals and Indivior agreed to combine in an all-stock merger of equals that will trade as Supernus, Inc. on Nasdaq, with Indivior shareholders owning 56.5 percent and receiving a 1 billion dollar special dividend before close.
Read this issue →